Clinical trialNCT05157581RecruitingObservational

Extracorporeal Photopheresis in Sezary Syndrome

SponsorOleg E. Akilov, MD, PhDEnrollment20Sezary Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6. A CT scan will be obtained at baseline and only repeated if pathology is present at baseline. The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Oleg E Akilov, MD, PhD
University of Pittsburgh
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University School of Medicine
Atlanta, Georgia, United States
Pamela B Allen, MD, MSc
Not, yet, recruiting
Cutaneous Translational Research Program - Johns Hopkins Medicine
Baltimore, Maryland, United States
Sima Rozati, MD, PhD
Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Oleg E Akilov, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Methoxsalen →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Apr 2023
Primary completion: 31 Dec 2028
Completion: 31 Dec 2028
Last update posted: 30 Dec 2025
Registered enrollment: 20
Registry id: NCT05157581

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.